Our Pharma Insights Blog
The rare disease landscape has hit a significant milestone early in 2026. On January 12th,…
One wrong decision when selecting an enteral feeding tube supplier can disrupt patient care overnight.…
In 2025, the US FDA approved 11 New Biological Entities (NBEs), representing a significant milestone…
In 2025, the US FDA approved 45 new drugs, including 34 New Chemical Entities (NCEs)…
In pharmaceutical development, choosing the right regulatory pathway can significantly influence timelines, costs, and overall…
Every breakthrough medication starts somewhere. That somewhere is either a New Chemical Entity (NCE) or…
A Reference Listed Drug (RLD) is an FDA-approved drug product identified in the Orange Book…
Biosimilars and generics are both affordable alternatives to brand-name medications. These drugs play a crucial…
The year 2024 proved to be a turning point for pharmaceutical innovation. From oncology to…
When it comes to drugs, one of the most common questions patients ask is, Are…
Serialization was once a regulatory checkbox. Today, it’s the backbone of compliant, efficient, and transparent clinical…
This article, authored by our Founder Salim Shaikh in International Clinical Trial Magazine, explores how…